Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, May 9, 2025– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.The transactions concern the vesting of restricted stock units (RSUs) by members...

Hellerup, 09/05/2025 (informazione.news - comunicati stampa - salute e benessere)

– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

The transactions concern the vesting of restricted stock units (RSUs) by members of the Board of Directors and the Executive Management of Bavarian Nordic A/S. For members of the Board of Directors, the RSU's were awarded as part of their remuneration for 2022, and in accordance with the decision by the Annual General Meeting on April 5, 2022. The transaction reported for President & CEO, Paul Chaplin concerns the vesting of RSUs awarded in 2022 as part of a retention scheme established in 2021, and the transaction for Chief Operating Officer, Russell Thirsk concerns the vesting of RSUs awarded in 2022 as part of a sign-on bonus. The three-year vesting period for the RSUs has now expired, and all conditions for release of the shares have been met.

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 17 / 2025

Attachment